Immunome, Inc.
NASDAQ:IMNM
11.02 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Immunome, Inc. |
Symbool | IMNM |
Munteenheid | USD |
Prijs | 11.02 |
Beurswaarde | 687,833,136 |
Dividendpercentage | 0% |
52-weken bereik | 8.97 - 30.958 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Clay B. Siegall Ph.D. |
Website | https://immunome.com |
An error occurred while fetching data.
Over Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)